Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension
SUNNYVALE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug,...